|
ICU & Emergency Medicine Product Line
When bleeding emergencies arise, urgent surgery is required, sepsis has taken hold, or multi-factor coagulation deficiencies are discovered, you require treatment options that work under the pressure you do to achieve fast and effective restoration of the body’s natural balance. Octapharma’s ICU product line has demonstrated excellent efficacy and tolerability in the treatment of this critical patient group. With so many variables to control, the ability to rely on your treatment options is essential.
Click here to review general information about the indications for the ICU & Emergency Medicine Product Line.
 |
|
|
Pharmaceutically licensed, SD treated fresh frozen plasma for transfusion. With more than 4’500’000 units used, octaplas® has set new standards in transfusion medicine. Available in 200ml bags in A, B, O and AB blood groups.
|
|
|
|
|
|
|
|
|
|
 |
|
|
octaplex® is Octapharma's state-of-the-art human prothrombin complex concentrate. Virus reduction measures include solvent detergent (SD) treatment and nanofiltration. octaplex® offers a good haemostatic balance of coagulation factors and inhibitors.
|
|
|
|
|
|
|
|
|
|
 |
|
|
atenativ® - High purity antithrombin concentrate for treatment of coagulation disturbances in connection with inherited and acquired antithrombin deficiency. atenativ® is double virus-inactivated by a combination of SD and heat treatment and is heparin free. Available in 500 IU, 1000 IU and 1500 IU vials.
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
albumin 5%
albumin 20%
albumin 25%
Protein solution for restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated.
|
|
|
|
|
|
|
|
|
|
Octapharma supports the development and education of best practice through continual clinical research, cooperation’s with industry associations, and regular educational symposiums. Octapharma works with the Plasma Protein Therapeutics Association to provide balanced and scientifically based evidence on the unique biochemical properties and appropriate clinical utilization of albumin. Twice a year, Octapharma hosts educational sessions involving international leaders in sepsis and disseminated intravascular coagulopathy research in Denmark.
|
|
 |
|
Octapharma will sponsor two satellite symposia at the upcoming ISBT Congress, June 7 - 12, 2008 in Macau SAR, China
May 27, 2008
Octapharma at WFH Congress, June 1 - 5, 2008, Istanbul, Turkey
May 24, 2008
Octapharma acquisition of a plasma fractionation plant in Springe, Germany from German Red Cross organizations
May 8, 2008
|
|
|
|
